US Patent US12611411B2 for Triple-Agent Cancer Therapy Granted to Cytometric Therapeutics
Summary
The USPTO granted patent US12611411B2 to Cytometric Therapeutics, Inc. for methods of treating cancer with a tri-agent therapy combining tamoxifen, gefitinib, and vinorelbine (TGV). The patent application was filed on September 15, 2022, and the granted patent contains 21 claims covering both sequential and concurrent administration regimens as well as cyclical and continuous metronomic dosing approaches.
“Disclosed are methods of treating cancer with a tri-agent therapy.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
The USPTO granted patent US12611411B2 to Cytometric Therapeutics, Inc. for a tri-agent cancer therapy combining tamoxifen, gefitinib, and vinorelbine. The patent covers methods of treating cancer including sequential and/or concurrent administration of the three agents, as well as both cyclical and continuous metronomic dosing regimens.
For pharmaceutical companies and researchers developing cancer treatments, this patent establishes intellectual property protection for a specific multi-agent therapeutic approach. Parties interested in developing similar combination therapies should conduct freedom-to-operate analyses to assess potential licensing needs from Cytometric Therapeutics.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Triple-agent therapy for cancer treatment
Grant US12611411B2 Kind: B2 Apr 28, 2026
Assignee
CYTOMETRIC THERAPEUTICS, INC.
Inventors
Larry Weisenthal, William Grace
Abstract
Disclosed are methods of treating cancer with a tri-agent therapy. The methods include a cancer treatment regimen with two or three different antineoplastic medications, including tamoxifen, gefitinib, and vinorelbine (TGV). The cancer treatment regimen can include sequential and/or concurrent administration of tamoxifen, gefitinib, and vinorelbine. The cancer treatment regimen can include sequential and/or concurrent administration of tamoxifen and gefitinib as adjuvants to a prescribed treatment. The cancer treatment regimen can be cyclical or can be a continuous metronomic treatment with metronomic dosing. The cancer treatment regimen can be cyclical and then can be followed by a continuous metronomic treatment with metronomic dosing.
CPC Classifications
A61K 31/5377 A61K 31/138 A61K 31/4745 A61K 2300/00 A61P 35/00
Filing Date
2022-09-15
Application No.
18689980
Claims
21
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.